China's pharmaceutical industry has formally entered the Three Kingdoms era
Source:Pujiang Optoelectronic Technology CO.LTD.Publication time：2018-07-02
In the past year, the domestic pharmaceutical industry frequency now giant integrated medicine section of the Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Pharmaceutical Group") with Shanghai Industrial Investment (Holdings) Co., Ltd. (hereinafter referred to as the "SIIC") is the first to achieve merger the establishment of a new on drugs; China pharmaceutical Group Corporation (hereinafter referred to as "Sinopharm") on April 12 this year, following last year's merger of China National Biotec Group, Inc. (hereinafter referred to as "Health Group") the successful restructuring of the Shanghai Institute of Pharmaceutical Industry (hereinafter referred to as "Medical Engineering Institute) established new Sinopharm; just 10 days before, the China Resources Group and the Beijing Municipal People's Government formally signed a" strategic cooperation framework agreement "on the common development of the pharmaceutical industry and the microelectronics industry, the official China Resources North sacs into her arms, and the establishment of the new China Resources. At this point, with the completion of the merger and reorganization of the Big Three domestic pharmaceutical, pharmaceutical industry since 2009, the amount of M & A transactions reached its highest level since 2000, significantly changed the competitive landscape of the pharmaceutical market, Chinese pharmaceutical industry has formally entered the era of the Three Kingdoms . New Sinopharm, China Resources, the new drug three seating scheduled, the industry bigwigs After the re-row seat surfaced recent national requirements in the country has taken to achieve the Group envisaged the formation of several pharmaceutical leaders.